{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:52:54Z","timestamp":1791082374179,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.molmed.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T20:08:15Z","timestamp":1718654895000},"page":"863-874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Erythropoietic protoporphyrias: updates and advances"],"prefix":"10.1016","volume":"30","author":[{"given":"Antoine","family":"Poli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Puy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neila","family":"Talbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-7025","authenticated-orcid":false,"given":"Laurent","family":"Gouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.05.006_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0140-6736(61)92427-8","article-title":"Erythropoietic protoporphyria a new porphyria syndrome with solar urticaria due to protoporphyrin\u00e6mia","volume":"278","author":"Magnus","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2024.05.006_bb0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2024.05.006_bb0015","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/blood.V93.6.2105.406k28_2105_2110","article-title":"Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation","volume":"93","author":"Gouya","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.006_bb0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2008.08.003","article-title":"C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload","volume":"83","author":"Whatley","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2024.05.006_bb0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/498620","article-title":"Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria","volume":"78","author":"Gouya","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2024.05.006_bb0030","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1046\/j.1432-1327.2000.01519.x","article-title":"Regulation of the expression of human ferrochelatase by intracellular iron levels","volume":"267","author":"Taketani","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.molmed.2024.05.006_bb0035","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nature11536","article-title":"Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts","volume":"491","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2024.05.006_bb0040","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2004-04-1566","article-title":"Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels","volume":"105","author":"Zhou","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.006_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108487","article-title":"Protoporphyrin IX-induced phototoxicity: mechanisms and therapeutics","volume":"248","author":"Hussain","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2024.05.006_bb0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","article-title":"The incidence of inherited porphyrias in Europe","volume":"36","author":"Elder","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.molmed.2024.05.006_bb0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41436-020-00951-8","article-title":"Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria","volume":"23","author":"Dickey","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.molmed.2024.05.006_bb0060","series-title":"GeneReviews","article-title":"Erythropoietic protoporphyria, autosomal recessive","author":"Balwani","year":"2017"},{"key":"10.1016\/j.molmed.2024.05.006_bb0065","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2133.2010.09631.x","article-title":"Molecular epidemiology of erythropoietic protoporphyria in the U.K","volume":"162","author":"Whatley","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamadermatol.2017.1557","article-title":"Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and x-linked protoporphyria","volume":"153","author":"Balwani","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2133.2006.07472.x","article-title":"Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life","volume":"155","author":"Holme","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2796.2010.02236.x","article-title":"Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical, and genetic characteristics","volume":"269","author":"Wahlin","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.molmed.2024.05.006_bb0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/1346-8138.16690","article-title":"Erythropoietic protoporphyria in the Netherlands: clinical features, psychosocial impact and the effect of afamelanotide","volume":"50","author":"Wensink","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0090","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.3390\/ijerph20075296","article-title":"Quality-adjusted life years in erythropoietic protoporphyria and other rare diseases: a patient-initiated EQ-5D feasibility study","volume":"20","author":"Barman-Aks\u00f6zen","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.molmed.2024.05.006_bb0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/PROM.S438892","article-title":"Development and content validation of novel patient-reported outcome measures to assess disease severity and change in patients with erythropoietic protoporphyria: the EPP Impact Questionnaire (EPIQ)","volume":"15","author":"Mathias","year":"2024","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.molmed.2024.05.006_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jmd2.12052","article-title":"Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X-linked protoporphyria","volume":"50","author":"Naik","year":"2019","journal-title":"JIMD Rep."},{"key":"10.1016\/j.molmed.2024.05.006_bb0105","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/diagnostics12051193","article-title":"Psychological aspect and quality of life in porphyrias: a review","volume":"12","author":"Granata","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.molmed.2024.05.006_bb0110","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jaad.2022.08.036","article-title":"Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria","volume":"89","author":"Dickey","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0115","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jaad.2020.11.074","article-title":"Visible light. Part II: photoprotection against visible and ultraviolet light","volume":"84","author":"Geisler","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0120","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12714","article-title":"Narrowband ultraviolet B phototherapy in erythropoietic protoporphyria: case series","volume":"170","author":"Sivaramakrishnan","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.05.006_bb0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2021.12.017","article-title":"Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: a case-control study","volume":"135","author":"Wensink","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2024.05.006_bb0135","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/s41436-021-01176-z","article-title":"Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain\u2014a patient-reported outcome efficacy measure","volume":"23","author":"Wensink","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.molmed.2024.05.006_bb0140","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/jamadermatol.2020.0352","article-title":"Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice","volume":"156","author":"Wensink","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0145","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/bjd.13598","article-title":"Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria","volume":"172","author":"Biolcati","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13023-020-01505-6","article-title":"Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide-a three years observational study","volume":"15","author":"Barman-Aks\u00f6zen","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.molmed.2024.05.006_bb0155","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1056\/NEJMoa2208754","article-title":"Dersimelagon in erythropoietic protoporphyrias","volume":"388","author":"Balwani","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.05.006_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114132","article-title":"Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: a systematic review","volume":"158","author":"Heerfordt","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molmed.2024.05.006_bb0165","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jamadermatol.2016.2303","article-title":"Novel treatment using cimetidine for erythropoietic protoporphyria in children","volume":"152","author":"Tu","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2022.102793","article-title":"Cimetidine for erythropoietic protoporphyria","volume":"38","author":"Heerfordt","year":"2022","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.molmed.2024.05.006_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/biom14010027","article-title":"Cimetidine does not inhibit 5-aminolevulinic acid synthase or heme oxygenase activity: implications for treatment of acute intermittent porphyria and erythropoietic protoporphyria","volume":"14","author":"Yasuda","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.molmed.2024.05.006_bb0180","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bjd.15893","article-title":"Osteoporosis in patients with erythropoietic protoporphyria","volume":"177","author":"Biewenga","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0185","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1182\/blood-2007-04-088120","article-title":"Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria","volume":"110","author":"Holme","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.006_bb0190","first-page":"1227","article-title":"Evidence based consensus guidelines for diagnosis and management of Protoporphyria-Related liver dysfunction in erythropoietic protoporphyria and X-Linked protoporphyria","volume":"89","author":"Levy","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2024.05.006_bb0195","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.dld.2021.08.007","article-title":"Liver involvement in patients with erythropoietic protoporphyria","volume":"54","author":"Wensink","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.molmed.2024.05.006_bb0200","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/lt.20620","article-title":"Liver transplantation for erythropoietic protoporphyria liver disease","volume":"11","author":"McGuire","year":"2005","journal-title":"Liver Transpl."},{"key":"10.1016\/j.molmed.2024.05.006_bb0205","article-title":"Management of erythropoietic protoporphyria with cholestatic liver disease: A case report","volume":"37","author":"Poli","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.molmed.2024.05.006_bb0210","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/lt.25632","article-title":"Management of patients with erythropoietic protoporphyria-related progressive liver disease","volume":"25","author":"Ardalan","year":"2019","journal-title":"Liver Transpl."},{"key":"10.1016\/j.molmed.2024.05.006_bb0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12328-014-0501-7","article-title":"A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion","volume":"7","author":"Honda","year":"2014","journal-title":"Clin. J. Gastroenterol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2014-07-584664","article-title":"Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria","volume":"126","author":"Egan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.006_bb0225","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/metabo11120798","article-title":"Iron, heme synthesis and erythropoietic porphyrias: a complex interplay","volume":"11","author":"Poli","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.molmed.2024.05.006_bb0230","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2169\/internalmedicine.0673-17","article-title":"Erythropoietic protoporphyria-related hepatopathy successfully treated with phlebotomy","volume":"57","author":"Yoshida","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.molmed.2024.05.006_bb0235","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.30543","article-title":"Clinical remission of delta-aminolevulinic acid dehydratase deficiency through suppression of erythroid heme synthesis","volume":"70","author":"Neeleman","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2024.05.006_bb0240","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1386-6346(00)00077-2","article-title":"A case of erythropoietic protoporphyria with liver cirrhosis suggesting a therapeutic value of supplementation with \u03b1-tocopherol","volume":"18","author":"Komatsu","year":"2000","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.molmed.2024.05.006_bb0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-105-1-27","article-title":"Iron therapy for hepatic dysfunction in erythropoietic protoporphyria","volume":"105","author":"Gordeuk","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.molmed.2024.05.006_bb0250","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.1840020613","article-title":"Effect of hematin administration to patients with protoporphyria and liver disease","volume":"2","author":"Bloomer","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2024.05.006_bb0255","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/lt.22341","article-title":"Liver transplantation for erythropoietic protoporphyria in Europe","volume":"17","author":"Wahlin","year":"2011","journal-title":"Liver Transpl."},{"key":"10.1016\/j.molmed.2024.05.006_bb0260","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10545-010-9272-6","article-title":"UK experience of liver transplantation for erythropoietic protoporphyria","volume":"34","author":"Dowman","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.molmed.2024.05.006_bb0265","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0009-9120(89)80081-5","article-title":"Hepatobiliary implications and complications in protoporphyria, a 20-year study","volume":"22","author":"Doss","year":"1989","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.molmed.2024.05.006_bb0270","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3324\/haematol.2020.272450","article-title":"A mutation in the iron-responsive element of ALAS2 is a modifier of disease severity in apatient suffering from CLPX associated erythropoietic protoporphyria","volume":"106","author":"Ducamp","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2024.05.006_bb0275","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/eci.12503","article-title":"Homeostasis of iron and hepcidin in erythropoietic protoporphyria","volume":"45","author":"Bossi","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.molmed.2024.05.006_bb0280","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ymgme.2018.12.012","article-title":"GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in human congenital sideroblastic anemia","volume":"128","author":"Daher","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2024.05.006_bb0285","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcmd.2014.07.017","article-title":"In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability","volume":"54","author":"Barman-Aks\u00f6zen","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.molmed.2024.05.006_bb0290","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymgme.2019.04.013","article-title":"Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria","volume":"128","author":"Barman-Aks\u00f6zen","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2024.05.006_bb0295","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fphar.2014.00176","article-title":"The IRP\/IRE system in vivo: insights from mouse models","volume":"5","author":"Wilkinson","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0300","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.26001","article-title":"Cell-type-specific insights into iron regulatory processes","volume":"96","author":"Mleczko-Sanecka","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0305","article-title":"A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria","volume":"33","author":"Balwani","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.molmed.2024.05.006_bb0310","first-page":"2921","article-title":"How I treat erythropoietic protoporphyria and X-linked protoporphyria","volume":"141","author":"Leaf","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.006_bb0315","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bjh.13612","article-title":"X-linked protoporphyria: iron supplementation improves protoporphyrin overload, liver damage and anaemia","volume":"173","author":"Landefeld","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0320","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3324\/haematol.2019.228270","article-title":"Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria","volume":"106","author":"Mirmiran","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2024.05.006_bb0325","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1038\/s41598-022-10089-z","article-title":"Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria","volume":"12","author":"Hagiwara","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2024.05.006_bb0330","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.chembiol.2021.02.021","article-title":"Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria","volume":"28","author":"Halloy","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0335","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.exphem.2016.07.003","article-title":"Effects of GlyT1 inhibition on erythropoiesis and iron homeostasis in rats","volume":"44","author":"Winter","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0340","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130111","article-title":"Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of \u03b2-thalassemia","volume":"4","author":"Matte","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2024.05.006_bb0345","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjh.17479","article-title":"Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent \u03b2-thalassaemia","volume":"194","author":"Taher","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2024.05.006_bb0350","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","article-title":"Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicent","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.molmed.2024.05.006_bb0355","doi-asserted-by":"crossref","first-page":"15649","DOI":"10.1073\/pnas.202607599","article-title":"The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria","volume":"99","author":"Jonker","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2024.05.006_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw6127","article-title":"The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria","volume":"5","author":"Wang","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2024.05.006_bb0365","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ajhg.2014.02.010","article-title":"Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria","volume":"94","author":"Oustric","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2024.05.006_bb0370","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ajhg.2018.12.021","article-title":"Erythroid-progenitor-targeted gene therapy using bifunctional TFR1 ligand-peptides in human erythropoietic protoporphyria","volume":"104","author":"Mirmiran","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2024.05.006_bb0375","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1093\/nar\/gkaa229","article-title":"Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria","volume":"48","author":"Halloy","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molmed.2024.05.006_bb0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/mthe.2001.0467","article-title":"Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection","volume":"4","author":"Richard","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.05.006_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2019.101582","article-title":"Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: a new treatment modality","volume":"29","author":"Wulf","year":"2020","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.molmed.2024.05.006_bb0390","article-title":"Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study","volume":"2","author":"Minder","year":"2021","journal-title":"Ther. Adv. Rare Dis."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142400128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142400128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:04:42Z","timestamp":1726373082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149142400128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S147149142400128X"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.05.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythropoietic protoporphyrias: updates and advances","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}